Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR1 | O14842 | 4/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.53 |
| ▸ | MMP9 | P14780 | 1/20 | 0.51 |
| ▸ | MMP8 | P22894 | 1/20 | 0.51 |
| ▸ | MMP13 | P45452 | 1/20 | 0.51 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | CTSA | P10619 | 1/20 | 0.46 |
| ▸ | LTB4R2 | Q9NPC1 | 1/20 | 0.46 |
| ▸ | FAAH | O00519 | 2/20 | 0.46 |
| ▸ | LMNA | P02545 | 2/20 | 0.45 |
| ▸ | PLA2G4B | P0C869 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | GPR88 | Q9GZN0 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13236738 | 0.91 | FFAR1 (0.47) | FFAR1SMN1; SMN2MMP9MMP8MMP13 | |
| SCHEMBL11294199 | 0.88 | MAPK1 (0.47) | FFAR1SMN1; SMN2MMP9MMP8MMP13 | |
| SCHEMBL2948148 | 0.87 | FFAR1 (0.68) | FFAR1SMN1; SMN2MMP9MMP8MMP13 | |
| SCHEMBL2947157 | 0.84 | FAAH (0.57) | FFAR1SMN1; SMN2MMP9MMP8MMP13 | |
| SCHEMBL2941508 | 0.84 | MMP9 (0.65) | FFAR1SMN1; SMN2MMP9MMP8MMP13 | |
| SCHEMBL2939695 | 0.83 | MMP9 (0.67) | FFAR1SMN1; SMN2MMP9MMP8MMP13 | |
| SCHEMBL2949131 | 0.83 | MMP9 (0.67) | FFAR1SMN1; SMN2MMP9MMP8MMP13 | |
| SCHEMBL9474072 | 0.82 | MMP9 (0.70) | FFAR1SMN1; SMN2MMP9MMP8MMP13 | |
| SCHEMBL2947981 | 0.81 | SMN1; SMN2 (0.74) | FFAR1SMN1; SMN2MMP9MMP8MMP13 | |
| SCHEMBL5149908 | 0.81 | HDAC4 (0.51) | FFAR1POLBCTSA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7750048-B2 | GPR40 agonists | JANSSEN PHARMACEUTICA NV (BE) | 2010-07-06 | — | — | US | claimed |
| US-20080176912-A1 | GPR40 AGONISTS | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-07-24 | — | — | US | claimed |
| EP-3443957-B1 | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF CANCER | LIMINAL BIOSCIENCES LTD (GB) | 2020-11-25 | — | — | EP | disclosed |
| CN-105997967-B | Compound and composition for treating cancer | 普罗米蒂克医药SMT有限公司 | 2019-08-23 | — | — | CN | disclosed |
| EP-3443957-A1 | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF CANCER | PROMETIC PHARMA SMT LIMITED (GB) | 2019-02-20 | — | — | EP | disclosed |
| EP-2632452-B1 | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF CANCER | PROMETIC PHARMA SMT LTD (GB) | 2018-09-26 | — | — | EP | disclosed |
| CN-105997967-A | Compounds and compositions for the treatment of cancer | 普罗米蒂克医药SMT有限公司 | 2016-10-12 | — | — | CN | disclosed |
| US-9439882-B2 | Compounds and compositions for the treatment of cancer | PROMETIC BIOSCIENCES INC. (CA) | 2016-09-13 | — | — | US | disclosed |
| US-9439882-B2 | Compounds and compositions for the treatment of cancer | PROMETIC BIOSCIENCES INC. (CA) | 2016-09-13 | — | — | US | disclosed |
| US-9439882-B2 | Compounds and compositions for the treatment of cancer | PROMETIC BIOSCIENCES INC. (CA) | 2016-09-13 | — | — | US | disclosed |
| CN-103347509-B | Compounds and compositions for the treatment of cancer | 普罗米蒂克生物科学公司 | 2016-06-08 | — | — | CN | disclosed |
| US-20130217645-A1 | Compounds and Compositions for the Treatment of Cancer | PROMETIC BIOSCIENCES INC. (CA) | 2013-08-22 | — | — | US | disclosed |
| US-20130217645-A1 | Compounds and Compositions for the Treatment of Cancer | PROMETIC BIOSCIENCES INC. (CA) | 2013-08-22 | — | — | US | disclosed |
| WO-2012097427-A1 | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF CANCER | PROMETIC BIOSCIENCES INC. (CA) | 2012-07-26 | — | — | WO | disclosed |
| US-7750048-B2 | GPR40 agonists | JANSSEN PHARMACEUTICA NV (BE) | 2010-07-06 | — | — | US | disclosed |
| US-7750048-B2 | GPR40 agonists | JANSSEN PHARMACEUTICA NV (BE) | 2010-07-06 | — | — | US | disclosed |
| US-7750048-B2 | GPR40 agonists | JANSSEN PHARMACEUTICA NV (BE) | 2010-07-06 | — | — | US | disclosed |
| US-20080176912-A1 | GPR40 AGONISTS | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-07-24 | — | — | US | disclosed |
| US-20080176912-A1 | GPR40 AGONISTS | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-07-24 | — | — | US | disclosed |
| US-20080176912-A1 | GPR40 AGONISTS | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-07-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130217645-A1 | Compounds and Compositions for the Treatment of Cancer | DCK, TOP2B, TOP2A | FFAR1 3574/4885SMN1; SMN2 3115/4885MMP9 4296/4885 |
| US-20080176912-A1 | GPR40 AGONISTS | GPR119, GPR65, GPR55 | FFAR1 8/4885SMN1; SMN2 3652/4885MMP9 4828/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.